Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

45 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Prolongation of interferon therapy for recurrent hepatitis C after living donor liver transplantation: analysis of predictive factors of sustained virological response, including amino acid sequence of the core and NS5A regions of hepatitis C virus.
Kawaoka T, Hiraga N, Takahashi S, Takaki S, Mitsui F, Tsuge M, Nagaoki Y, Kimura Y, Hashimoto Y, Katamura Y, Hiramatsu A, Waki K, Imamura M, Kawakami Y, Aikata H, Tashiro H, Ohdan H, Chayama K. Kawaoka T, et al. Among authors: mitsui f. Scand J Gastroenterol. 2010 Dec;45(12):1488-96. doi: 10.3109/00365521.2010.505657. Epub 2010 Jul 22. Scand J Gastroenterol. 2010. PMID: 20662615
Absence of viral interference and different susceptibility to interferon between hepatitis B virus and hepatitis C virus in human hepatocyte chimeric mice.
Hiraga N, Imamura M, Hatakeyama T, Kitamura S, Mitsui F, Tanaka S, Tsuge M, Takahashi S, Abe H, Maekawa T, Ochi H, Tateno C, Yoshizato K, Wakita T, Chayama K. Hiraga N, et al. Among authors: mitsui f. J Hepatol. 2009 Dec;51(6):1046-54. doi: 10.1016/j.jhep.2009.09.002. Epub 2009 Sep 23. J Hepatol. 2009. PMID: 19853955
Predictive value of the IL28B polymorphism on the effect of interferon therapy in chronic hepatitis C patients with genotypes 2a and 2b.
Kawaoka T, Hayes CN, Ohishi W, Ochi H, Maekawa T, Abe H, Tsuge M, Mitsui F, Hiraga N, Imamura M, Takahashi S, Kubo M, Tsunoda T, Nakamura Y, Kumada H, Chayama K. Kawaoka T, et al. Among authors: mitsui f. J Hepatol. 2011 Mar;54(3):408-14. doi: 10.1016/j.jhep.2010.07.032. Epub 2010 Sep 19. J Hepatol. 2011. PMID: 21112660
Elimination of hepatitis C virus by short term NS3-4A and NS5B inhibitor combination therapy in human hepatocyte chimeric mice.
Ohara E, Hiraga N, Imamura M, Iwao E, Kamiya N, Yamada I, Kono T, Onishi M, Hirata D, Mitsui F, Kawaoka T, Tsuge M, Takahashi S, Abe H, Hayes CN, Ochi H, Tateno C, Yoshizato K, Tanaka S, Chayama K. Ohara E, et al. Among authors: mitsui f. J Hepatol. 2011 May;54(5):872-8. doi: 10.1016/j.jhep.2010.08.033. Epub 2010 Oct 26. J Hepatol. 2011. PMID: 21145818
Amino acid substitutions in core and NS5A regions of the HCV genome can predict virological decrease with pegylated interferon plus ribavirin therapy.
Kitamura S, Tsuge M, Hatakeyama T, Abe H, Imamura M, Mori N, Saneto H, Kawaoka T, Mitsui F, Hiraga N, Takaki S, Kawakami Y, Aikata H, Takahashi S, Ohishi W, Ochi H, Hayes CN, Chayama K. Kitamura S, et al. Among authors: mitsui f. Antivir Ther. 2010;15(8):1087-97. doi: 10.3851/IMP1674. Antivir Ther. 2010. PMID: 21149915
Importance of serum concentration of adefovir for Lamivudine-adefovir combination therapy in patients with lamivudine-resistant chronic hepatitis B.
Mitsui F, Tsuge M, Kimura T, Kitamura S, Abe H, Saneto H, Kawaoka T, Miki D, Hatakeyama T, Hiraga N, Imamura M, Kawakami Y, Aikata H, Takahashi S, Hayes CN, Igarashi H, Morimoto K, Shimizu M, Chayama K. Mitsui F, et al. Antimicrob Agents Chemother. 2010 Aug;54(8):3205-11. doi: 10.1128/AAC.01372-09. Epub 2010 May 24. Antimicrob Agents Chemother. 2010. PMID: 20498322 Free PMC article. Clinical Trial.
45 results